These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 18181675)

  • 1. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
    O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
    Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance between central and local laboratory HER2 testing from a community-based clinical study.
    Reddy JC; Reimann JD; Anderson SM; Klein PM
    Clin Breast Cancer; 2006 Jun; 7(2):153-7. PubMed ID: 16800975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
    Diaz NM
    Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
    Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
    Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
    Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
    Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.
    Hofmann M; Stoss O; Gaiser T; Kneitz H; Heinmöller P; Gutjahr T; Kaufmann M; Henkel T; Rüschoff J
    J Clin Pathol; 2008 Jan; 61(1):89-94. PubMed ID: 17412870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HER2 ASCO guidelines. The answer to everything?].
    Burandt E; Sauter G
    Pathologe; 2010 Oct; 31 Suppl 2():285-91. PubMed ID: 20740285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
    Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2--a discussion of testing approaches in the USA.
    Thor A
    Ann Oncol; 2001; 12 Suppl 1():S101-7. PubMed ID: 11521714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
    Giltnane JM; Molinaro A; Cheng H; Robinson A; Turbin D; Gelmon K; Huntsman D; Rimm DL
    Arch Pathol Lab Med; 2008 Oct; 132(10):1635-47. PubMed ID: 18834223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
    Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
    J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
    Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
    Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
    Roche PC; Suman VJ; Jenkins RB; Davidson NE; Martino S; Kaufman PA; Addo FK; Murphy B; Ingle JN; Perez EA
    J Natl Cancer Inst; 2002 Jun; 94(11):855-7. PubMed ID: 12048274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of HER2 breast cancer testing.
    Cuadros M; Villegas R
    Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):1-7. PubMed ID: 18685491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
    Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
    Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.
    McCullough AE; Dell'orto P; Reinholz MM; Gelber RD; Dueck AC; Russo L; Jenkins RB; Andrighetto S; Chen B; Jackisch C; Untch M; Perez EA; Piccart-Gebhart MJ; Viale G
    Breast Cancer Res Treat; 2014 Feb; 143(3):485-92. PubMed ID: 24395109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma.
    Bozzetti C; Negri FV; Lagrasta CA; Crafa P; Bassano C; Tamagnini I; Gardini G; Nizzoli R; Leonardi F; Gasparro D; Camisa R; Cavalli S; Silini EM; Ardizzoni A
    Br J Cancer; 2011 Apr; 104(9):1372-6. PubMed ID: 21487407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance of HER2 Immunohistochemistry and Fluorescence
    Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
    Anticancer Res; 2017 Jun; 37(6):3323-3329. PubMed ID: 28551685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.